2. Laboratoire d''Immunopharmacologie des Tumeurs, INSERM U-236, CNRS ERA 844, Centre Paul Lamarque, BP 5054, 34033 Montpellier Cédex, France;1. Université Pierre et Marie Curie, UER 61, 4 Place Jussieu, Tour 32, 75005 Paris, France
Abstract:
Interleukin-2 (IL-2) activity production by stimulated peripheral blood lymphocytes (PBL) from solid tumor bearing cancer patients was lower than in normal subjects. Natural-killer (NK) cell activity in the PBL of cancer patients was very significantly correlated to IL-2 activity production (P less than 0.001). These results might suggest a central role for IL-2 in the immune dysfunctions in cancer patients, and the possible use of IL-2 as an immunological response modifier in these patients.